FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

Oxford, UK– 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or“the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news